For instance, a combination therapy of CTLA-4 inhibitor (Ipilimumab), CIML NK cell infusion, and interleukin-15 superagonist (N-803) is currently being evaluated for the treatment of advanced head and neck cancer (Clinical trials. This evidence concerns the gene CTLA4 and head and neck cancer.